Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adaptimmune Therapeutics's quarterly market cap
declined
from Dec. 2024 ($137.88 Mil) to Mar. 2025 ($50.80 Mil) but then
increased
from Mar. 2025 ($50.80 Mil) to Jun. 2025 ($63.53 Mil).
Adaptimmune Therapeutics's annual market cap
declined
from Dec. 2022 ($240.20 Mil) to Dec. 2023 ($180.14 Mil) and
declined
from Dec. 2023 ($180.14 Mil) to Dec. 2024 ($137.88 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Adaptimmune Therapeutics's Enterprise Value for Today is $28.98 Mil.
Adaptimmune Therapeutics (OTCPK:ADAPY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Adaptimmune Therapeutics Market Cap Related Terms
Adaptimmune Therapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adaptimmune Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptimmune Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Adaptimmune Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Adaptimmune Therapeutics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptimmune Therapeutics (ADAPY) has a Market Cap of $6.36 Mil as of Aug. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Market Cap too high?
Adaptimmune Therapeutics' current Market Cap is $6.36 Mil. The Biotechnology industry median Market Cap is 123.85. Adaptimmune Therapeutics' value of $6.36 Mil is 94.9% below this industry median.
How does Adaptimmune Therapeutics' Market Cap compare to BCLI and APRE?
Adaptimmune Therapeutics' Market Cap of $6.36 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 123.85. Adaptimmune Therapeutics' value of $6.36 Mil is 94.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 123.85, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adaptimmune Therapeutics's current Market Cap of $6.36 Mil is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Adaptimmune Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 123.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptimmune Therapeutics's current Market Cap is $6.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Market Cap of $6.36 Mil. The current Market Cap is $6.36 Mil and 94.9% below the Biotechnology industry median of 123.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Market Cap is $6.36 Mil as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADAPY has been successfully added to your 
